Anti-Bacterial Agents
Cefiderocol
Cephalosporins
Pneumonia
Pneumonia, Ventilator-Associated

Cephalosporins

Cephalosporins are -lactam antimicrobials used to manage various infections caused by both gram-positive and gram-negative bacteria. The 5 generations of cephalosporins demonstrate efficacy in treating skin and soft tissue infections, pneumonia, meningitis, and other infections. Cefiderocol is a novel siderophore cephalosporin that exhibits remarkable antibacterial activity. This drug has been approved by the US Food and Drug Administration (FDA) to treat complicated urinary tract infections and ventilator-associated pneumonia caused by highly resistant gram-negative bacteria, including Klebsiella pneumonia, Proteus mirabilis, Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Cefiderocol emerges as a promising therapeutic option for challenging infections, with literature reviews suggesting its potential in combating strains resistant to carbapenems. Importantly, cefiderocol is the only recently approved -lactam agent exhibiting in vitro activity against carbapenem-resistant A baumannii (CRAB) isolates. According to the Infectious Diseases Society of America guidelines, cefiderocol should be reserved for cases of CRAB infections that remain unresponsive to other antibiotics or when intolerance to alternative agents prohibits their use. This activity provides clinicians with comprehensive insights into indications, mechanisms of action, contraindications, monitoring protocols, potential adverse drug reactions, and clinical toxicology associated with cephalosporins. This activity also provides healthcare professionals with essential knowledge and necessary tools to make informed decisions, promptly identify adverse effects, and optimize patient outcomes through vigilant monitoring and effective cephalosporin utilization, ensuring antibiotic therapy proficiency.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.